• Find people
• Intranet

Colorectal Cancer Precision Medicine Clara Montagut

Publications 2024 (8)

• Pericay C^*, Montagut C, Reina JJ, Melian M, Alcaide J, Tarazona N, Ruiz-Casado A, González-Flores E, Graña B, Gravalos MC. SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023). 2024: (en Premsa).
• Hilmi M, Khati I, Turpin A, Andremont A, Burdet C, Grall N, Vidal J, Bousquet PJ, Rousseau B^*, Bihan-benjamin CL. Association between the antibiotics use and recurrence in patients with resected colorectal cancer: EVADER-1, a nation-wide pharmaco-epidemiologic study. Digest Liver Dis 2024: (en Premsa).
• Cabrero-de las Heras S, Hernandez X, Gonzalez A, Losa F, Soler G, Bugés C, Baraibar I, Esteve A, Pardo-Cea MÁ, Ree AH, Martínez-Bosch N, Nieva M, Musulén E, Meltzer S, Lobato T, Vendrell-Ayats C, Queralt C, Navarro P, Montagut C, Grau-Leal F, Camacho D, Legido R, Mulet-Margalef N, Martínez-Balibrea E^*. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment. Biomed Pharmacother 2024; 176: 116857.
• Ríos-Hoyo A, Monzonis X, Vidal J, Linares JL, Montagut C^*. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Front Pharmacol 2024; 15: 1398419 (Acceptat).
• Bach R^*, Corbera A, Sumarroca A, Gimeno J, Guix M. A Case of Peritoneal Carcinomatosis After Hyperprogression in Human Papillomavirus-Positive (HPV+) Oropharyngeal Squamous Cell Carcinoma. Cureus . 2024; 16(6): e62509 (Acceptat).
• Bessa X^*, Vidal J, Balboa JC, Márquez C, Duenwald S, He Y, Raymond V, Faull I, Burón A, Álvarez C, Castells X, Bellosillo B, Montagut C^*. High accuracy of a blood ctDNA-based multimodal test to detect colorectal cancer. Ann Oncol 2024; 34(12): 1187-1193.
• Solé L, Lobo T, Cabré J, Gonzalez A, Fernández-Ibarrondo L, Marruecos L, Guix M, Cuatrecasas M, Lopez S, Bellosillo B, Torres F, Iglesias M, Bigas A, Espinosa L^*. Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients. BBA-Mol Cell Res 2024; 1871(3): 119658.
• Santana-Hernández S, Suárez J, Servitja S, Berenguer-Molins P, Costa-Garcia M, Comerma L, Rea A, Perera J, Menéndez S, Arpí O, Bermejo B, Martínez-Larrad MT, Cejalvo JM, Comino-Méndez I, Pascual J, Alba E, López-Botet M, Rojo F, Rovira A, Albanell J, Muntasell A^*. NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer. J Exp Clin Canc Res 2024; 43(1): 10.